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Alzheimer’s disease cerebrospinal fluid
biomarker in cognitively normal subjects
Jon B. Toledo,1 Henrik Zetterberg,2,3 Argonde C. van Harten,4 Lidia Glodzik,5
Pablo Martinez-Lage,6 Luisella Bocchio-Chiavetto,7,8 Lorena Rami,9 Oskar Hansson,10,11
Reisa Sperling,12 Sebastiaan Engelborghs,13,14 Ricardo S. Osorio,5 Hugo Vanderstichele,15
Manu Vandijck,16 Harald Hampel,17,18 Stefan Teipl,19,20 Abhay Moghekar,21 Marilyn Albert,21
William T. Hu,22 Jose A. Monge Argile´s,23 Ana Gorostidi,24 Charlotte E. Teunissen,25
Peter P. De Deyn,13,14 Bradley T. Hyman,12 Jose L. Molinuevo,9 Giovanni B. Frisoni,7,26
Gurutz Linazasoro,6 Mony J. de Leon,5 Wiesje M. van der Flier,4,27 Philip Scheltens,4
Kaj Blennow,2,28 Leslie M. Shaw1 and John Q. Trojanowski1 on behalf of the Alzheimer’s
Disease Neuroimaging Initiative
In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency
of abnormal cerebrospinal ﬂuid levels of Alzheimer’s disease biomarkers including: total tau, phosphorylated tau and amyloid-b1-42.
Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex measurements were selected
for this study. Each centre sent nine new cerebrospinal ﬂuid aliquots that were used to measure total tau, phosphorylated tau and
amyloid-b1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements;
therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40–84 years old).
Amyloid-b amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the
pathological cerebrospinal ﬂuid Alzheimer’s disease cut-off values for cerebrospinal ﬂuid amyloid-b1-42 and total tau, respectively.
While gender did not affect these biomarker values, APOE genotype modiﬁed the age-associated changes in cerebrospinal ﬂuid
biomarkers such that APOE 4 carriers showed stronger age-related changes in cerebrospinal ﬂuid phosphorylated tau, total tau
and amyloid-b1-42 values and APOE 2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classiﬁed as
amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegen-
eration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1%
at 44 years to 16% at 85 years, but its frequency was not affected byAPOE genotype. The amyloid-positive neurodegeneration-positive
frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal ﬂuid amyloid-b1-42 levels were already
frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal ﬂuid amyloid-b1-42, phosphorylated tau and total tau
across the lifespan without inﬂuencing the frequency of subjects with suspected non-amyloid pathology.
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Introduction
Alzheimer’s disease is characterized by the deposition of intra-
cellular tau proteins into neuroﬁbrillary tangles and amyloid-b
peptides into extracellular amyloid plaques. However, these
pathologies also are present in cognitively normal subjects
with advancing age (Hyman et al., 2012) and neuroﬁbrillary
tangles can appear even before the fourth decade of life
(Braak and Del Tredici, 2011), although these early changes
may be below the biomarker diagnostic threshold (Jack et al.,
2013a). Tau and amyloid-b can be measured in the CSF. CSF
tau levels correlate with the number of neuroﬁbrillary tangles
in the brain, whereas amyloid-b1-42 levels show an inverse
correlation with brain amyloid plaques (Strozyk et al.,
2003; Tapiola et al., 2009; Toledo et al., 2012), which
makes them informative as Alzheimer’s disease biomarkers.
Changes in CSF tau and amyloid-b biomarker levels appear
between one and two decades before the expected time of
onset of dementia in subjects who develop Alzheimer’s
disease due to autosomal dominant mutations (Bateman
et al., 2012; Reiman et al., 2012; Fagan et al., 2014).
Similarly population-based studies have shown that low
CSF amyloid-b1-42 levels in cognitively normal elderly subjects
predict future Alzheimer’s disease dementia up to 8 years in
advance (Skoog et al., 2003; Gustafson et al., 2007), while
approximately one-third of elderly cognitively normal subjects
have an Alzheimer’s disease-like proﬁle of tau and amyloid-b
CSF biomarker levels (Shaw et al., 2009; De Meyer et al.,
2010) and similarly pathological amyloid burden as measured
by PET has been found in cognitively normal subjects
(Aizenstein et al., 2008). Taken together with data on
Alzheimer’s disease imaging biomarkers, these ﬁndings have
led to a model that predicts successive appearance of abnor-
mal biomarker values before the onset of cognitive changes,
which leads at a later stage to dementia and impairments in
activities of daily living (Jack et al., 2013a). Recently, a study
that used Pittsburgh compound B (PIB) PET as biomarker for
amyloid-b load as well as ﬂuorodeoxyglucose (FDG) PET and
hippocampal MRI volume as biomarkers for neurodegenera-
tion described how changes started at the end of the sixth
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decade and differed based on gender and APOE genotype in
a population-based sample of ageing (Jack et al., 2014). In the
current study, amyloid-b status [negative (A) or positive
(A+ )] and neurodegeneration status [negative (N) or posi-
tive (N+ )] were established based on pathological CSF
Alzheimer’s disease cut-off values for CSF amyloid-b1-42 and
total tau, respectively, and the goal of this study was to de-
scribe the association of these CSF biomarkers with ageing,
gender and APOE genotype in a large multicentre cohort of
healthy controls.
Materials and methods
Cohorts
All of the subjects included in the current study were healthy
controls although some of the subjects presented with a diag-
nosis of subjective cognitive decline. The subjective cognitive
decline group included subjects who indicated that they pre-
sented cognitive decline, but did not show any impairment the
applied neuropsychological battery, i.e. did not test below a
score of 1.5 standard deviations or more below the mean of
healthy controls. Subjects belonged to the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) (Weiner et al., 2013), the
Parkinson Progression Marker Initiative (PPMI) (Kang et al.,
2013a), the University of Pennsylvania Penn Memory Center/
Alzheimer disease Center Core (Toledo et al., 2014a),
Amsterdam Dementia Cohort (van Harten et al., 2013; van
der Flier et al., 2014), NYU Center for Brain Health, CITA
Alzheimer, IRCCS Centro San Giovanni di Dio, Brescia, Italy
(Paternico et al., 2012), Lund University (Stomrud et al.,
2007), University Hospital of Alicante (Berenguer et al.,
2014), IDIBAPS-Hospital Clinic de Barcelona, DZNE
Rostock (Teipel et al., 2014), Emory University and
BIOCARD (Moghekar et al., 2013). ADNI and PPMI meas-
urements were performed at the University of Pennsylvania
and the NYU Center for Brain Health samples were measured
in the Clinical Neurochemistry Laboratory at Gothenburg
University (Supplementary material).
CSF measurements were performed in the different cohorts
either by a single analyte enzyme-linked immunosorbent assay
(ELISA; INNOTEST for Research Use Only reagents;
Fujirebio Europe) or the multiplex Luminex assay format
(INNO-BIA AlzBio3 for Research Use Only reagents;
Fujirebio Europe). The monoclonal antibodies that were used
in the assays for capture and reporting for detection of amyl-
oid-b1-42, total tau and phosphorylated tau are described in
Supplementary Table 1 and have been previously described
in more detail (Vanderstichele et al., 2008; Kang et al.,
2013b). Supplementary Table 2 summarizes the CSF collection
and storage procedures in the different centres. Each centre
sent nine aliquots to the Gothenburg University laboratory;
three aliquots were selected to represent the CSF amyloid-b1-42
range of values, three aliquots were selected to represent the
CSF total tau range of values and the last three aliquots were
selected to represent the CSF phosphorylated tau range of
values. Each of the aliquots represented the ﬁrst, second and
third tertile of the biomarker values. The ELISA method to
measure CSF tau and amyloid-b1-42 levels in all the nine
aliquots sent by each centre for this study was performed as
described previously (Palmqvist et al., 2014). In addition, the
Luminex method was also used to measure the CSF samples
if enough CSF volume was left after the ELISA measurements.
Statistics
Comparisons of quantitative and qualitative variables between
the different cohorts were performed using an ANOVA and
Fisher’s exact test, respectively. Correlations between the original
CSF tau and amyloid-b1-42 values that were obtained in each of
the centres and the reference values generated by the Gothenburg
laboratory were tested using Spearman rank correlation. Centres
whose data showed a correlation coefﬁcient 40.7 when com-
pared to the ELISA values obtained by the Gothenburg
University laboratory were included in the analyses. To transform
values from each centre into a common scale a robust linear
regression was applied, using the values of each of the shipping
centres as a predictor and the values obtained by the Gothenburg
laboratory as an outcome. Supplementary Tables 3 and 4 sum-
marize Spearman rank correlation rho values and the results of
the robust regression including the intercept and slope that were
used to transform the data from each centre.
In all of these analyses, APOE genotypes were grouped into
three categories: (i) 2 carriers (2/2 and 2/3); (ii) 3/3
genotype; and (iii) 4 carriers (3/4 and 4/4). 2/4 subjects
were not included due to small sample size. To test which
variables were associated with the CSF biomarkers studied
here, we tested linear models that included APOE genotype,
gender and age and squared age as predictors. Power trans-
formations were applied as necessary to achieve a normal dis-
tribution of the data. A backward stepwise procedure was
applied to select the predictors. In all models, squared age
and gender were excluded as predictors. We then modelled
the biomarker changes across the different ages of the subjects
included here by applying multivariate adaptive regression
splines (MARS) to the data, analysing each of the APOE geno-
type groups separately to better capture biomarker dynamics
as a function of age across the lifespan. A multinomial regres-
sion model that included age, gender and APOE groups (see
above), was used to estimate the frequencies associated with
each of the groups of CSF tau and amyloid-b results for the
range of ages of these subjects from 45 to 85 years old, includ-
ing three cubic restricted splines at 55, 65 and 75 years to
allow age-dependent trends. Mean values and 95% conﬁdence
intervals (CI) were estimated applying a parametric bootstrap
using 1000 multivariable normal deviates as previously
described (Jack et al., 2014). This method was also applied
to estimate frequency differences between groups and the cor-
responding 95% CIs. Differences were deemed signiﬁcant if 0
was not included in the CI. Analyses were performed using R
version 3.0.3 (R Foundation for Statistical Computing).
Results
Cohorts
The study includes data from 15 different cohorts whose
samples were measured in 10 different centres, each one
composed of nine to 270 subjects (Table 1). Cohorts dif-
fered in gender (P50.0001) and age (P50.0001) of the
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subjects, but not with respect to the presence of their
APOE 4 alleles (P = 0.15).
Comparison of CSF tau and
amyloid-b values to data generated
by the Gothenburg laboratory
CSF total tau, phosphorylated tau and amyloid-b1-42 meas-
urements for the different cohorts were performed in 12
centres, one of them being the University of Gothenburg
laboratory that also generated reference values to perform
the transformations in this study. Ten of the centres that
had performed the measurements sent nine CSF aliquots of
participants included in this study to the University of
Gothenburg to be able to transform values across the dif-
ferent cohorts. Two laboratories did not include aliquots
for this analysis: the ﬁrst laboratory had performed a pre-
vious adjustment run in a larger sample and the second one
was the Gothenburg laboratory that measured total tau,
phosphorylated tau and amyloid-b1-42 in all these CSF ali-
quots. In most cases, there was enough CSF available to
perform ELISA and Luminex measurements for each of
the aliquots. Supplementary Fig. 1 presents the values for
each of the three analytes measured in the reference labora-
tory using both platforms on the same samples. Amyloid-
b1-42 and total tau values were highly correlated across
platforms (r = 0.91 and r = 0.98, respectively), whereas
phosphorylated tau values showed a lower correlation
(r = 0.66).
Notably, when the values obtained at the Gothenburg
laboratory were compared with the original values ob-
tained in the different centres that shipped the samples,
we observed that correlations varied across centres
(Supplementary Tables 3, 4 and Supplementary Figs 2
and 3). For the following analyses, we selected centres
that showed a spearman rank correlation5 0.70, which
correspond to Cohorts C–H and L–O, which included
1233 subjects and transformed CSF amyloid-b1-42, total
tau and phosphorylated tau values according to the results
of the robust regression (Supplementary Tables 3 and 4).
Subjects aged 40 to 84 were included in the following ana-
lyses to avoid extreme age ranges with small number of
subjects.
Association of amyloid-b1-42 and tau
with age and APOE groups
Age and APOE genotype, but not gender, were associated
with CSF biomarker values (Table 2). When we compared
CSF values in young (age 50–64 years) and old participants
(age 65–80 years) in an analysis adjusted for APOE, total
tau (P5 0.0001) and phosphorylated tau (P5 0.0001)
were increased in the group composed of older subject,
whereas there were no differences in amyloid-b1-42 values
(P = 0.07) between both age-deﬁned groups.T
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We then analysed the changes in the CSF biomarker
values across different ages stratiﬁed by APOE genotype
(Fig. 1). We included gender, in addition to age, in all
the MARS models, but gender was not selected as a pre-
dictor in any of the models.
Subjects with APOE 4 carriers showed higher CSF tau
and lower amyloid-b values than APOE 3/3 subjects. The
largest effect was observed for amyloid-b1-42 values;
whereas amyloid-b1-42 values remained stable up to the be-
ginning of the seventh decade in the healthy controls with-
out any 4 alleles, amyloid-b1-42 levels of healthy controls
with one or two 4 alleles showed a decrease starting
during the ﬁfth decade of life until a plateau was reached
at the middle of the eighth decade. APOE 2 carriers
showed a similar pattern of amyloid-b1-42 changes levels
as APOE 3/3 subjects, although APOE 2 carriers pre-
sented overall higher values. On the other hand, total tau
and phosphorylated tau levels remained stable until the be-
ginning of the seventh decade in subjects with APOE 3/3
and 4 carriers and it was in this age range that these
groups differed in the rate of increase in their values.
Total tau and phosphorylated tau value changes were simi-
lar in APOE 2 carriers as subjects with APOE 3/3
genotype.
To study possible differences between the cognitively
normal and subjective memory decline subjects, there
were three cohorts that included both groups of partici-
pants (Cohorts G, H and L); however, Cohort L was
excluded because it mainly consisted of subjective
memory decline subjects. Analysis was limited to the
APOE 3/3 genotype due to sample size (84 cognitively
normal and 52 subjective memory decline participants).
There were no differences between the two groups
(Supplementary Table 5).
When we transformed the Luminex CSF amyloid-b1-42
cut-off deﬁned by Shaw et al. (2009) into ELISA reference
values using the transformation formula obtained from the
robust regression applied to the University of Pennsylvania
values, we obtained a value of 543.5 pg/ml, which is close
to the one applied in the Gothenburg laboratory (550 pg/
ml) determined following International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) guide-
lines (IFCC, 1987). Conversely, the transformed total tau
cut-off value was higher than the one described by the
Gothenburg laboratory, namely 616 pg/ml compared with
400 pg/ml. In our study we selected the mean value of the
cut-offs from the two aforementioned cohorts to deﬁne
pathological amyloid-b1-42 (546.7 pg/ml) and total tau
(508 pg/ml) levels.
Amyloid and neurodegeneration
positive groups based on CSF
amyloid-b1-42 and total tau values
For these analyses, amyloid status [negative (A) or posi-
tive (A+ )] and neurodegeneration status [negative (N) or
positive (N+ )] was established based on CSF Alzheimer’s
disease cut-off values for CSF amyloid-b1-42 and total tau,
respectively. In all groups, the frequency of subjects with-
out abnormal biomarkers was lower in older subjects,
whereas the frequency in the A+N group showed only
slightly higher frequency. Both the frequency of AN+
and A+N+ subjects was higher in older subjects, but the
former reached a plateau whereas the latter showed a
stable increase (Fig. 2). At 45 years of age, 76% were clas-
siﬁed as AN whereas their frequency was only 32% at
85 years; and A+N frequency showed small differences
during the same period (22% versus 24%). The AN+
and A+N+ groups showed larger age-related differences:
1% at 45 years versus 16% at 85 years and 1% at 54 years
versus 28% at 85 years, respectively. Male and female sub-
jects showed similar frequencies for the different groups.
On the other hand APOE genotype strongly inﬂuenced
the frequency of the different groups. In the youngest par-
ticipants included, 4 carriers presented a higher frequency
in the A+ group than the 3/3 carriers (absolute 17%
difference) and the 2 carrier (absolute 26% difference)
groups that were larger in the eldest subjects (absolute
21.2% for the 3/3 participants and 41.6% for the 2
carriers). On the other hand, there were no differences in
the frequency of N+ subjects in the different groups
deﬁned by APOE genotype; and even when the frequency
difference became larger in the older participants, there was
a signiﬁcant overlap, which was a result of the complete
overlap in the AN+ group and the larger differences
observed in the eldest participants in the A+N+ group
(Fig. 3). A more detailed analysis of the effect of APOE
genotypes on the frequency of each of the four groups is
presented in Fig. 4, where the frequency of each group is
compared based on the APOE genotype, and the APOE
3/3 genotype is selected as the reference and compared to
the 2 and 4 carriers. Therefore values above zero repre-
sent a higher frequency in the carrier groups (either APOE
2 or 4) compared to the APOE 3/3 group and values
below zero represent the opposite ﬁnding. In the AN
groups, the frequency difference between APOE 3/3 sub-
jects and APOE 4 carriers remained largely similar indi-
cating that differences between groups appeared mainly at
earlier ages. On the other hand, older APOE 2 carriers
showed a larger difference compared to the older APOE
3/3 subjects, indicating that the protective effect of these
alleles acted throughout the age span studied here. Older
APOE 2 carriers showed a larger difference in the A+N
group frequency compared to APOE 3/3 subjects,
whereas APOE 4 carriers showed similar differences inde-
pendently of age. However, APOE 4 carriers showed a
smaller A +N frequency difference compared to APOE
3/3 subjects with increasing age. This decrease in the
A+N frequency difference was accompanied by a larger
A +N+ frequency difference in APOE 4 carriers.
Conversely, APOE 2 carriers showed a lower frequency
of A +N+ that showed a larger difference in older ages
when compared to APOE 3/3 subjects. Finally, the
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different APOE genotype groups showed no difference and
overlapped with each other for the AN+ category, indi-
cating that only age was associated with changes in this
group. Although female subjects showed increased
frequency of A +N subjects and decreased frequency of
AN across the studied ages, differences were small and
included the zero value, therefore lacking statistical
signiﬁcance.
Figure 1 CSF amyloid-b1-42, total tau and phosphorylated tau181 levels in association with ageing in healthy controls stratified
by APOE genotype. Dashed lines represent the cut-off points for the biomarkers.
Table 2 Association between CSF biomarkers and APOE genotypes
Age APOE 2/3 & 2/2 APOE 3/4 & 4/4 Gender (male)
Coef. P-value Coef. P -value Coef. P -value Coef. P -value
Amyloid-b1-42 0.12 50.0001 0.23 0.009 0.40 50.0001 0.018 0.75
Total tau 0.45 50.0001 0.012 0.88 0.21 0.0007 0.03 0.59
Phosphorylated tau 0.40 50.0001 0.080 0.37 0.25 0.0001 0.03 0.62
Only the results for the best model are shown here.
Coef. = standardized coefficient of the linear regression. Models are adjusted for age and gender.
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Discussion
In this large cohort of healthy control subjects covering a
wide age range over the life span we found that already
starting in the ﬁfth decade of life there is a signiﬁcant
number of healthy control subjects who show evidence of
abnormal CSF amyloid-b1-42 values, and that APOE
genotypes signiﬁcantly modiﬁed CSF amyloid-b1-42 values
with the 4 allele strongly associated with the lower of
amyloid-b1-42 values at younger ages and the 2 allele asso-
ciated with overall lower values at older ages. The APOE
4 allele also associated with the age at which CSF amyl-
oid-b1-42 began declining (A +N group) and additionally,
in subjects with abnormal CSF amyloid-b1-42, associated
with the age at which total tau started changing
(A +N+ ). Conversely, we did not observe any APOE geno-
type effects on total tau levels in subjects without patho-
logical amyloid-b1-42 values (AN+ group).
Figure 2 Estimated frequency of pathological amyloid-b (A) and neurodegeneration (N) categories according to age of the
subjects. Plots represent all subjects and subjects stratified by gender and APOE genotype. Due to smaller sample size subjects with 2 alleles
were not stratified by gender. Shaded areas represent 95% CI.
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The availability of longitudinal studies and their combin-
ation with Alzheimer’s disease biomarkers ﬁndings has led
to a deeper understanding of the long preclinical stages of
Alzheimer’s disease (Jack et al., 2013a) and this is corro-
borated by the ﬁnding of Alzheimer’s disease pathology in
autopsies of elderly cognitively normal subjects (Montine
et al., 2012). Recently, results from studies that included
cognitively normal subjects with Alzheimer’s disease, auto-
somal dominant mutations and a well characterized ex-
pected age of onset of dementia have shown that several
Alzheimer’s disease biomarkers show changes already one
to two decades before the onset of cognitive decline
(Bateman et al., 2012; Reiman et al., 2012; Fagan et al.,
2014). Models based on longitudinal CSF and PET amyloid
measures have shown that changes in these Alzheimer’s
disease biomarkers take place more than one decade
before clinical disease onset (Skoog et al., 2003;
Gustafson et al., 2007; Jack et al., 2013b; Toledo et al.,
2013c; Villemagne et al., 2013). However, the modelling of
these changes also has included stable cognitively normal
subjects therefore altering the timeframes of these changes
as well as probably underestimating the real rate of bio-
marker changes (Toledo et al., 2013c).
In our study we found that already by the ﬁfth decade of
life 420% of subjects show abnormal CSF amyloid-b1-42
values and that the frequency of A +N subjects remained
relatively stable across the different ages, whereas the
AN+ and A+N+ categories increased their frequencies
starting early in the sixth decade. However, these two cate-
gories differed at the end of the eighth decade, with AN+
group reaching a plateau and the A+N+ group still show-
ing an exponential increase. We also observed that while
the difference in tau biomarker values in middle aged and
elderly healthy controls was signiﬁcant, this was not the
case for amyloid-b1-42.
The stable frequency of the A+N can be explained by
the fact that this is a transitory category of subjects who
were AN and later progress to A+N+ and later on to
mild cognitive impairment and Alzheimer’s disease. This
would indicate that there is equilibrium in the rate of sub-
jects entering and leaving this category. Another factor is
the increasing frequency of this category in the 3/3 sub-
jects that is accompanied by a decrease in the subjects with
4 alleles. Nevertheless the overall frequency of A + par-
ticipants (independently of neurodegeneration status) was
higher with increasing age. The increase in AN+
Figure 3 Frequency of A + , N + , A + N and A + N + stratified by APOE-defined groups.
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frequency antecedes overall the A+N+ frequency increase,
but reaches an early plateau. The underlying pathologies
and longitudinal prognosis of the AN+ is still
largely unknown, but vascular pathology, frontotemporal
lobar degeneration or primary age-related tauopathy
(Crary et al., 2014; Jellinger et al., 2015). It has been pro-
posed that it can represent non-Alzheimer’s disease pathol-
ogies and also precede the A+N+ category (Jack et al.,
2014). The fact that besides Alzheimer’s disease, patholo-
gies associated with increased CSF total tau values are
Figure 4 Differences in the frequency of the four biomarker groups in subjects with APOE 3/ 3 genotype compared subjects
who are 2 or 4 allele carriers. The lines above the black dashed line indicate that the plotted group has a higher frequency of the studied
biomarker category. For the gender plots values above the 0 represent a higher frequency for females, whereas values below 0 represent a higher
frequency in males. Shaded areas represent 95% CI.
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mainly the less frequent acute head trauma and stroke, and
prion diseases, would indicate that the latter hypothesis is
more plausible. Both of these hypotheses explain a plateau
of the frequency with ageing either due to a transition to
A+N+ with an exhausted pool of AN subjects in aged
individuals or due to an earlier age of onset and later de-
crease of incidence in non-Alzheimer’s disease pathologies.
A third explanation is the high prevalence of coincident
neurodegenerative and non-neurodegenerative diseases
that cause dementia in elderly individuals (Kovacs et al.,
2013; Toledo et al., 2013a; Rahimi and Kovacs, 2014;
Jellinger and Attems, 2015) that cannot be accurately pre-
dicted by the current biomarkers (Toledo et al., 2012,
2013b) and therefore it can be expected that these subjects
are classiﬁed in the A+N+ group. It is interesting that the
exponential increase in the frequency of healthy controls in
the A+N+ category mirrors the exponential prevalence
observed for Alzheimer’s disease, only differing by an ear-
lier onset in the middle of the sixth decade instead of in the
middle of the seventh decade.
APOE genotype showed an important but differential
effect on the frequency of the different groups across
ages. APOE 4 carriers showed relatively stable difference
in AN frequency across ages when compared to APOE
3/3 subjects, 18% lower, but APOE 2 carriers showed
an increasingly larger percentage of subjects in the AN
category compared to APOE 3/3 subjects with ageing
(the frequency went from 10% higher to 19% higher
than 3/3 subjects; Fig. 4). Nevertheless, for the oldest
subjects, the difference in A+N frequency between
APOE 3/3 subjects and APOE 4 carriers was smaller
due to a slightly higher percentage of A+N in APOE 3/
3 subjects and a smaller percentage of A +N in APOE
4 carriers (Fig. 2). This most likely is linked to the fact
that APOE 4 carriers start to progress to A+N and
A+N+ at a younger age followed by progression to mild
cognitive impairment and Alzheimer’s disease which leads
to a depletion of the AN category and acts as a survival
bias.
Interestingly, the strongest effect of the APOE genotype
was observed for the A+N+ group. Whereas in the AN
and A+N only one of the APOE-deﬁned groups showed
changes in differences compared to the 3/3 group (and
the other showed stable differences parallel to the x-axis)
and no differences were found in the AN+ group, in the
A+N+ group APOE 2 and 4 carriers showed opposite
changes when compared to subjects with 3/3 genotype.
With ageing there was a higher frequency of the A+N+
group in APOE 4 carriers compared to APOE 3/3 sub-
jects whereas there was a decreasing frequency of A +N+
subjects in APOE 2 carriers. This indicates that APOE
genotype is a strong modiﬁer for the transition from
A+N to A+N+ and of total tau changes in subjects
with pathological amyloid-b1-42 levels.
It is also noteworthy that APOE genotype status did not
affect the frequency of the AN+ group, which em-
phasizes that these subjects, who would ﬁt the suspected
non-amyloid pathology category (SNAP) (Jack et al., 2012),
represent mostly subjects who do not have underlying
Alzheimer’s disease pathology. This result is important for
modelling total tau changes because APOE genotype might
differentially affect CSF total tau values depending upon the
presence or absence of pathological Alzheimer’s disease-like
CSF amyloid-b1-42 levels. Nevertheless, it has been described
that this category might later transition to A+N+ (Jack
et al., 2013c) as discussed above. Our results would indicate
that the presence of signiﬁcant amyloid pathology, esti-
mated in our study by CSF amyloid-b1-42 values below
the cut-off point, should be present to present a signiﬁcant
APOE genotype-related increase of tau pathology as mea-
sured by CSF tau levels. This ﬁnding agrees with a previous
neuropathological study that estimated that the increase in
tau pathology associated to the presence of APOE 4 al-
leles was mainly indirectly mediated through an increase in
amyloid pathology (Mungas et al., 2014), although a lesser
direct effect was also present. Nonetheless, in this study we
are classifying subjects as having normal and abnormal
values and a detailed analysis with CSF or tau PET meas-
urements would be needed to evaluate the presence of a
direct effect on tau pathology as described in previous
cell and animal models (Huang et al., 2001; Harris et al.,
2003). However, it must be taken into account that signiﬁ-
cant increases of CSF total tau and phosphorylated tau
values are only seen in two neurodegenerative disease,
namely Alzheimer’s disease and prion diseases, and there-
fore CSF tau values are not representative of tau burden
present in frontotemporal lobar degeneration due to tau
pathology, which we cannot estimate with the current bio-
markers (Toledo et al., 2012).
One previous study performed a similar analysis to the
one we present here, but this study was carried out in a
population-based cohort (Jack et al., 2014) and presented
additional differences. First, in the Jack et al. (2014) study,
younger subjects were almost entirely classiﬁed as AN
and there was an increase in the frequency of A+N sub-
jects that reached a plateau followed by a decrease in aged
subjects. This difference between our study and the Jack
et al. (2014) study could be due to differences in CSF
and PET amyloid measures. Recently it was shown that
CSF and amyloid PET measures are associated for a limited
mid-range values that includes the cut-offs that are used for
diagnostic purposes and that the association between both
measures is modiﬁed by the APOE genotype (Toledo et al.,
2015). Therefore the cut-offs for abnormal amyloid-b
values offer consistent results across platforms (CSF im-
munoassays and PET scans) and methodologies (different
PET scan processing pipelines) to establish the cut-offs
(Toledo et al., 2015). The difference between these two
measures of amyloid-b pathology might explain why, des-
pite signiﬁcant agreement between both measures (Landau
et al., 2013; Toledo et al., 2015), there is a signiﬁcant
number of subjects who are classiﬁed discordantly for
each biomarker measure with most discordant subjects
being classiﬁed as having abnormal CSF amyloid-b1-42
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levels while having normal amyloid-b amyloid PET scans.
The disagreement decreases as subjects become more cog-
nitively impaired (Mattsson et al., 2015) and this could
indicate that CSF biomarker changes precede amyloid
PET changes at least in a subset of subjects. One potential
limitation of the study is the lack of amyloid-b1-40 meas-
urements to calculate the CSF amyloid-b1-42/amyloid-b1-40
ratio, which could classify some participants as A even if
their CSF amyloid-b1-42 values are below the cut-off, due to
the constitutively low values for the amyloid-b peptides.
However, it has been described that the value of the amyl-
oid-b1-42/amyloid-b1-40 ratio might be related to the im-
munoassay method (Hertze et al., 2010) and the assay we
used in this study did not seem to be affected. In addition,
the diagnostic performance of the amyloid-b42/tau ratio
was not improved when the amyloid-b1-42/amyloid-b1-40
ratio was used instead of amyloid-b1-42 values (Spies
et al., 2010). Therefore we favour the hypothesis that
CSF amyloid biomarker changes precede PET amyloid bio-
marker changes. Longitudinal follow-up of these subjects
will be needed to ascertain the implication of low CSF
amyloid-b1-42 values in middle-aged healthy controls. On
the other hand there is little agreement between the differ-
ent neurodegeneration biomarkers (as opposed to amyloid
biomarkers) (Toledo et al., 2014b). However, the overall
frequency observed in the eldest subjects was similar in the
Mayo clinic and our sample offering converging results on
the prevalence of biomarker-based preclinical Alzheimer’s
disease stages.
We found a non-signiﬁcant higher percentage of A +N
participants and lower percentage of AN participants in
females compared to males. This is consistent with previous
results that also reported higher but not signiﬁcant amyloid
PET values in females (Jack et al., 2015) and the previously
discussed study from the same group that reported higher
frequency of A+N participants in females compared to
males, although the latter study did not indicate if differ-
ences were signiﬁcant and did not perform a formal com-
parison (Jack et al., 2014).
Previously, the association between age, gender and CSF
Alzheimer’s disease biomarkers has been studied in smaller
studies using different analytical approaches. For example,
Sjo¨gren et al. (2001) described a positive correlation be-
tween age and CSF total tau levels without any association
with CSF amyloid-b1-42 levels in a sample of 231 subjects,
and suggested age-adjusted cut-offs for total tau levels. This
most likely represents an increased frequency of preclinical
Alzheimer’s disease associated with ageing and therefore we
consider that cut-offs should not be adjusted based on age.
In another study with 81 subjects, Paternico et al. (2012)
described the association with age and CSF total tau, but
they found no interaction with APOE and no association
with age for CSF amyloid-b1-42. On the other hand,
Peskind et al. (2006) found an association between CSF
amyloid-b1-42 levels and age and that this association was
modiﬁed by APOE genotype, with APOE 4 cognitively
normal carriers showing an earlier change and lower
amyloid-b1-42 levels in elder subjects, but the latter study
did not include CSF tau measurements. In an ageing study
by Glodzik-Sobanska et al. (2009) an association between
APOE genotype and CSF total tau and phosphorylated tau
values but not with amyloid-b1-42/ amyloid-b1-40 was
described (Glodzik-Sobanska et al., 2009). The association
between the APOE 4 allele and low CSF amyloid-b1-42
levels has recently been shown to depend on APOE 4
carriers having also increased cortical amyloid deposition
as evaluated by PET scanning, indicating a higher number
of preclinical Alzheimer’s disease cases in APOE 4 carriers
(Lautner et al., 2014). In our study, we found an associ-
ation between all three studied CSF biomarkers and age
and APOE genotype as described above. The association
of APOE genotype with all three CSF biomarkers can be
explained by the large number of samples we studied across
a large age span which allowed us to have a representative
number of subjects in each of the APOE groups. In add-
ition, most of the studies apply linear analyses, which do
not follow the biomarker dynamics that have been
described in elderly individuals with longitudinal biomarker
studies (Jack et al., 2013b; Toledo et al., 2013c; Villemagne
et al., 2013) and we conﬁrmed in the large analyses per-
formed herein in a cross-sectional population encompassing
a wider age range. It will be important to study longitu-
dinal clinical changes in middle-aged individuals to conﬁrm
previous ﬁndings between baseline CSF amyloid-b1-42
values and memory decline (Li et al., 2014).
Our study has four main limitations: samples were not
drawn from population based samples, measurements were
performed in different laboratories using two different
assays, CSF amyloid-b1-40 levels were not available and
clinical and biomarker longitudinal data were not available.
Thus, recruitment of cognitively normal subjects in specia-
lized centres might lead to biased recruitment and not rep-
resent the general population. Notably, however, this bias
can go in either direction as these subjects might have per-
sonal and familial reasons to be included in Alzheimer’s
disease biomarker studies, but also the inclusion criteria
might be stricter and therefore include healthier subjects
like the ones included in clinical trials. In addition, these
healthy controls tend to have a higher education level than
the general population. Although two different platforms
were used for the measurements of CSF amyloid-b1-42
and total tau, the values obtained were highly correlated
between both assays, as previously described (Fagan et al.,
2011; Irwin et al., 2012; Wang et al., 2012; Le Bastard
et al., 2013). Another important observation was the fact
that there were inter-laboratory differences. To control for
this we measured nine aliquots from each centre in the
Gothenburg laboratory and selected those subjects whose
CSF tau and amyloid-b values were highly correlated for
further study here and could therefore be transformed. This
emphasizes the well-established fact that each laboratory
must validate its own CSF tau and amyloid-b cut-offs
and cannot adopt the ones described in other laboratories
even using the same assay. A better solution is the
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availability of a common standard with associated cut-off
values in all biomarker laboratories. Finally, the CSF amyl-
oid-b1-42/amyloid-b1-40 ratio has been suggested as a
method to account for subjects who constitutively have
low values for the amyloid-b peptides in the CSF and there-
fore some of our cases might be false positives.
Our results indicate that Alzheimer’s disease-like CSF
amyloid-b1-42 positivity appears already in the ﬁfth
decade of life in healthy controls, which has important im-
plications for clinical trials targeting prevention or elimin-
ation of amyloid-b deposits, but also indicates that there is
a signiﬁcant interval between the time AN subjects pro-
gress to the A+N+ category, which represents an import-
ant therapeutic window for disease modifying therapies.
This is because only the A+N+ category mimics the
Alzheimer’s disease CSF biomarker proﬁle and total tau
reﬂects brain neuroﬁbrillary tangle burden which is closely
associated with neurodegeneration, and shows a stronger
correlation with cognitive symptoms than amyloid-b amyl-
oid deposition (Toledo et al., 2013a) thereby suggesting
that there is time window that might span almost 10
years for intervening with Alzheimer’s disease prevention
strategies. Finally APOE genotype strongly modiﬁes the
observed CSF biomarker proﬁle and classiﬁcation into pre-
clinical stages with 2 alleles showing a lifetime protective
effect.
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